Figure 3
Figure 3. Time to 2 consecutive positive CMV hybrid capture assays. (A) Kaplan-Meier plot of time to 2 consecutive positive CMV DNA hybrid capture assays by CMV donor/recipient serostatus among HSC transplant recipients that did not receive sirolimus-tacrolimus prophylaxis. (B) Kaplan-Meier plot of time to 2 consecutive positive CMV DNA hybrid capture assays by CMV donor/recipient serostatus among HSC transplant recipients that received sirolimus-tacrolimus prophylaxis. (C) Kaplan-Meier plot of time to 2 consecutive CMV DNA hybrid capture assays stratified by sirolimus-tacrolimus GVHD prophylaxis and incident grades II-IV GVHD.

Time to 2 consecutive positive CMV hybrid capture assays. (A) Kaplan-Meier plot of time to 2 consecutive positive CMV DNA hybrid capture assays by CMV donor/recipient serostatus among HSC transplant recipients that did not receive sirolimus-tacrolimus prophylaxis. (B) Kaplan-Meier plot of time to 2 consecutive positive CMV DNA hybrid capture assays by CMV donor/recipient serostatus among HSC transplant recipients that received sirolimus-tacrolimus prophylaxis. (C) Kaplan-Meier plot of time to 2 consecutive CMV DNA hybrid capture assays stratified by sirolimus-tacrolimus GVHD prophylaxis and incident grades II-IV GVHD.

Close Modal

or Create an Account

Close Modal
Close Modal